Related Experiment Video
Updated: Jul 10, 2026
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
The effect of celecoxib on tissue factor expression in pancreatic cancer cells
Hui-yuan Wang1, Yin-mo Yang, Yan Zhuang
1Department of General Surgery, Xuanwu Hospital of Capital Medical University, Beijing 100053, China.
Background:
Tissue factor (TF) is overexpressed in many malignant tumours and is linked to the pathogenesis and prognosis of such malignancies. In vitro studies have proved that reduced expression of TF has inhibitory effect on the angiogenesis and cell proliferation of the malignant tumour. Therefore, TF suppression has been raised as a possible treatment for malignant tumours. Here we investigated the effect of celecoxib on TF expression induced by tumour necrosis factor alpha (TNFalpha) in PANC-1 cells and a possible molecular mechanism underlying the celecoxib effect.
Methods:
Various doses of celecoxib solution were added to standard cell numbers of PANC-1 cells mixed with equal dose of TNFalpha for 6 hours. The expression of tissue factor was detected quantitatively by Western blot, whilst the activation of nuclear factor kappaB was tested by electromobility shift assay.
Results:
As the doses of celecoxib increased, the tissue factor expression was decreased in PANC-1 cells and so was the activation of nuclear factor kappaB.
Conclusions:
Celecoxib can downregulate the expression of tissue factor induced by TNFalpha in PANC-1 cells. This antitumour effect of celecoxib can be explained indirectly via its suppressive role in activation of nuclear factor kappaB.
Insights
Celecoxib effectively reduces tissue factor (TF) expression in PANC-1 cancer cells, a key factor in tumor growth. This suppression is linked to inhibiting nuclear factor-kappaB activation, offering a potential new cancer treatment strategy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Tissue factor (TF) is overexpressed in malignant tumors, contributing to cancer progression and poor prognosis.
- TF suppression shows potential for inhibiting tumor angiogenesis and cell proliferation.
- Investigating TF regulation is crucial for developing novel cancer therapies.
Purpose of the Study:
- To examine the effect of celecoxib on tumor necrosis factor alpha (TNFα)-induced tissue factor (TF) expression in PANC-1 cells.
- To elucidate the molecular mechanisms underlying celecoxib's impact on TF expression.
Main Methods:
- PANC-1 cells were treated with varying doses of celecoxib and TNFα.
- Tissue factor expression was quantified using Western blot analysis.
- Nuclear factor-kappaB (NF-κB) activation was assessed via electrophoretic mobility shift assay (EMSA).
Main Results:
- Celecoxib dose-dependently decreased tissue factor expression in PANC-1 cells.
- Celecoxib also inhibited the activation of nuclear factor-kappaB (NF-κB).
Conclusions:
- Celecoxib downregulates TNFα-induced tissue factor expression in PANC-1 cells.
- The anti-tumor effect of celecoxib may be mediated through the suppression of NF-κB activation.
